ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2313

Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT)

Vibeke Strand1, Regina Rendas-Baum2, George J. Joseph3, Chieh-I Chen4, Hubert van Hoogstraten5, T. W. J. Huizinga6 and Mark C. Genovese7, 1Biopharmaceutical Consultant, Portola Valley, CA, 2QualityMetric Inc, Lincoln, RI, 3Global Health Economics & Outcomes Research (HEOR), Sanofi, Bridgewater, NJ, 4Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 7Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: clinical trials, quality of life, RCT, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Health Services Research Poster III: Patient Reported Outcomes, Patient Education and Preferences

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Sarilumab is a human
monoclonal antibody (mAb) directed against the soluble IL-6 receptor (sIL-6R),
administered subcutaneously (SC) every 2 weeks (q2w).  In the phase 3 RCT
MOBILITY study (NCT01061736), sarilumab 150 mg and 200 mg SC q2w+MTX
demonstrated efficacy in patients (pts) with moderate-to-severe RA1
and was generally well tolerated. Patients treated with sarilumab also experienced
significantly greater improvements in HRQoL, fatigue and sleep compared with
placebo.2 Understanding the clinical importance of group differences
can be enhanced by assessing treatment benefit based on the proportion of
patients who report improvements meeting or exceeding minimum clinically important
differences (MCID). These analyses compared the percentages of patients who
reported MCIDs at week 24 across treatment groups.

Methods: The intent-to-treat
population included 1,197 patients randomized 1:1:1 to placebo+MTX, sarilumab
150 mg q2w+MTX, or sarilumab 200 mg q2w+MTX. PROs included Patient Global
Assessments (PtGA), Pain by VAS, HAQ-DI, SF-36v2 and FACIT-Fatigue. Patients
were classified as responders if their change scores were ≥ MCID for that PRO. A
binary logistic model with responder classification as the response and
treatment group, prior use of biologic agents and region as fixed effects was
used to estimate differences from placebo in response rates (RR) and numbers
needed to treat (NNT).

Results: RRs in sarilumab were significantly
better than placebo for all PROs with exception of SF-36 Mental Component
Summary and Mental Health domain scores with sarilumab 150 mg and Role
Emotional domain in both active treatment groups. Compared to placebo, there
were an additional 15%-21% of responders by PtGA, 14%-17% by Pain-VAS, 10%-13%
by Fatigue, 12% by HAQ-DI, 18%-21% by PCS and 17% by MCS (150 mg only). There
were 9% – 21% more responders by 7 of the 8 SF-36v2 domains (200 mg). NNTs ranged
from 4.7 (PCS; 200 mg) to 9.7 (FACIT-Fatigue; 150 mg) similarly favoring sarilumab
vs placebo.

Conclusion: More patients
receiving sarilumab+MTX reported changes in PROs ≥MCID, resulting in
small NNTs, indicating a significantly greater likelihood of clinically
meaningful improvement with active treatment than placebo+MTX.

References:

 1. Genovese MC, Fleischmann R, Kivitz A, et al.
Sarilumab Plus Methotrexate In Patients With Active Rheumatoid Arthritis And
Inadequate Response To Methotrexate: Results Of A Phase III Study. Arthritis
& Rheumatology Vol. 76, No. 6, June 2015, pp 1424-1437.

 2. Strand V, Joseph G, Hoogstraten H, et al. Impact of
Sarilumab on Health-Related Quality of Life (HRQoL), Fatigue, and Sleep in
Rheumatoid Arthritis Patients at Week 24 – Results of a Phase 3, Randomized,
Double-Blind, Placebo-Controlled, Multi-Center Study. Poster presented at the
ACR/AHRP Annual Meeting, Boston, US; 10-14 November, 2014.

 


Disclosure: V. Strand, Sanofi-Aventis Pharmaceutical, 5,Regeneron, 5,AbbVie, 5,Alder, 5,Amgen, 5,BMS, 5,Celgene, 5,Genetech, 5,Janssen Pharmaceutica Product, L.P., 5,Novartis Pharmaceutical Corporation, 5,Pfizer Inc, 5,UCB, 5,Abbvie, 6,Amgen, 6,BMS, 6,Celgene, 6,Genetech, 6,Janssen Pharmaceutica Product, L.P., 6,Novartis Pharmaceutical Corporation, 6,Pfizer Inc, 6,Sanofi/Regeneron, 6,UCB, 6; R. Rendas-Baum, Sanofi-Aventis Pharmaceutical, 5,Regeneron, 5; G. J. Joseph, Sanofi-Aventis Pharmaceutical, 3,Sanofi-Aventis Pharmaceutical, 1; C. I. Chen, Regeneron Pharmaceuticals, Inc., 1,Regeneron Pharmaceuticals, Inc., 3; H. van Hoogstraten, Sanofi-Aventis Pharmaceutical, 3,Sanofi-Aventis Pharmaceutical, 1; T. W. J. Huizinga, Sanofi-Aventis Pharmaceutical, 5; M. C. Genovese, Sanofi-Aventis Pharmaceutical, 2,Sanofi-Aventis Pharmaceutical, 2,Regeneron, 5,Regeneron, 2.

To cite this abstract in AMA style:

Strand V, Rendas-Baum R, Joseph GJ, Chen CI, van Hoogstraten H, Huizinga TWJ, Genovese MC. Responder Rates and Numbers Needed to Treat Based on Clinically Meaningful Improvements in Patient Reported Outcomes (PROs) Including Health-Related Quality of Life (HRQoL) after Sarilumab Treatment during a Phase III Randomized Controlled Trial (RCT) [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/responder-rates-and-numbers-needed-to-treat-based-on-clinically-meaningful-improvements-in-patient-reported-outcomes-pros-including-health-related-quality-of-life-hrqol-after-sarilumab-treatment-d/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/responder-rates-and-numbers-needed-to-treat-based-on-clinically-meaningful-improvements-in-patient-reported-outcomes-pros-including-health-related-quality-of-life-hrqol-after-sarilumab-treatment-d/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology